Is there any role for ascertaining somatostatin-receptor status with a DOTATATE PET scan in prostatic adenocarcinoma with neuroendocrine features to consider lanreotide along with chemotherapy?

Great question! The easy answer is no--regarding current standard of care treatments. This is not an FDA-approved treatment. However, this touches on the larger issue of we don't really know/understand what it means 'neuroendocrine' prostate cancer is. Ongoing work is better defining the molecular characteristics of prostate cancer along the spectrum of adenocarcinoma -> small cell with all of the variations in between. Some groups have ongoing studies looking at different types of radiolabeled ...